InCarda Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $30M

  • Investors
  • 8

InCarda Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to offer a novel approach to treating cardiovascular conditions and diseases. The company's lead treatment leverages the ability of inhaled therapy to deliver medicine in the first pass to cardiac tissue, presenting a small and effective dose of drug directly to affected regions of the heart, enabling doctors to treat paroxysmal atrial fibrillation and atrial arrhythmia in a simplified way.

Contact Information

Formerly Known As
Pleiades Cardio-Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7533 South Center View Court
  • Suite 4257
  • West Jordan, UT 84084
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 7533 South Center View Court
  • Suite 4257
  • West Jordan, UT 84084
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InCarda Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 21-Oct-2020 $30M Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 20-Nov-2018 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 28-Apr-2015 Completed Clinical Trials - General
2. Later Stage VC (Series A) 17-Dec-2014 $567K $877K Completed Generating Revenue
1. Angel (individual) 01-Oct-2012 $310K $310K Completed Generating Revenue
To view InCarda Therapeutics’s complete valuation and funding history, request access »

InCarda Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B2
Series B1 39,656,993 $0.001000 $0.04 $0.46 $0.46 1x $0.46 18.36%
Series A 18,844,440 $0.001000 $0.03 $0.38 $0.38 1x $0.38 8.72%
To view InCarda Therapeutics’s complete cap table history, request access »

InCarda Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer a novel approach to treating cardiovascular conditions and dis
Drug Discovery
West Jordan, UT
15 As of 2025

Burlington, MA
 

Montreal, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InCarda Therapeutics Competitors (28)

One of InCarda Therapeutics’s 28 competitors is Cardurion, a Venture Capital-Backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cardurion Venture Capital-Backed Burlington, MA
DalCor Pharmaceuticals Venture Capital-Backed Montreal, Canada
Istesso Private Equity-Backed London, United Kingdom
Acesion Pharma Venture Capital-Backed Frederiksberg, Denmark
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
You’re viewing 5 of 28 competitors. Get the full list »

InCarda Therapeutics Patents

InCarda Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025217305-A1 Devices, kits, and methods for delivering medication via the lungs Pending 10-Apr-2024
EP-4444417-A1 Inhaled therapy for cardiac arrhythmia Pending 09-Dec-2021
EP-4444417-A4 Inhaled therapy for cardiac arrhythmia Pending 09-Dec-2021
US-20250332152-A1 Inhaled therapy for cardiac arrhythmia Pending 09-Dec-2021
WO-2023107640-A1 Inhaled therapy for cardiac arrhythmia Inactive 09-Dec-2021 A61K31/4458
To view InCarda Therapeutics’s complete patent history, request access »

InCarda Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InCarda Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innoviva Holding Company Minority
UCSF Innovation Ventures Venture Capital Minority
Deerfield Management Venture Capital Minority
HealthCap Venture Capital Minority
Sofinnova Investments Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

InCarda Therapeutics FAQs

  • When was InCarda Therapeutics founded?

    InCarda Therapeutics was founded in 2009.

  • Where is InCarda Therapeutics headquartered?

    InCarda Therapeutics is headquartered in West Jordan, UT.

  • What is the size of InCarda Therapeutics?

    InCarda Therapeutics has 15 total employees.

  • What industry is InCarda Therapeutics in?

    InCarda Therapeutics’s primary industry is Drug Discovery.

  • Is InCarda Therapeutics a private or public company?

    InCarda Therapeutics is a Private company.

  • What is the current valuation of InCarda Therapeutics?

    The current valuation of InCarda Therapeutics is .

  • What is InCarda Therapeutics’s current revenue?

    The current revenue for InCarda Therapeutics is .

  • How much funding has InCarda Therapeutics raised over time?

    InCarda Therapeutics has raised $77.9M.

  • Who are InCarda Therapeutics’s investors?

    Innoviva, UCSF Innovation Ventures, Deerfield Management, HealthCap, and Sofinnova Investments are 5 of 8 investors who have invested in InCarda Therapeutics.

  • Who are InCarda Therapeutics’s competitors?

    Cardurion, DalCor Pharmaceuticals, Istesso, Acesion Pharma, and Renova Therapeutics are some of the 28 competitors of InCarda Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process